Latest Breaking News On - Oberland capital - Page 2 : comparemela.com

Humacyte: Upcoming BLA, Pivotal Data, Decent Cash, Excellent Opportunity (NASDAQ:HUMA)

Humacyte: Upcoming BLA, Pivotal Data, Decent Cash, Excellent Opportunity (NASDAQ:HUMA)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Dale sanderSuraj kaliaRevenue interest liabilityOberland capital

Humacyte, Inc (NASDAQ:HUMA) Q3 2023 Earnings Call Transcript

Operator: Good afternoon, ladies and gentlemen, and welcome to the Humacyte Third Quarter Results Conference Call. Currently, all participants are in a listen-only mode.

New yorkUnited statesSuraj kaliaJosh jenningsLaura niklasonDale sanderLauren marekHeather prichardAlpha healthcare acquisition corpCorporate developmentDepartment of defenseBiggest private equity companies byHumacyte incCall transcript novemberHumacyte third quarter results conferenceChief executive officer

Curis Provides Third Quarter 2023 Business Update

Curis Provides Third Quarter 2023 Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJames dentzerRoche groupDrug administrationExchange commissionCuris incPrnewswire curis incAim leukemiaTakeaim lymphomaRecent operationalTakeaim leukemiaAim lymphomaOrphan drug designationNote regarding forward looking statementsSecurities litigation reform actOberland capital

Zealand Pharma Announces Financial Results for the First Half of 2023

Company announcement - No. 28 / 2023 Zealand Pharma Announces Financial Results for the First Half of 2023 Strong progress across R&D pipeline and significant strengthening of the balance. -Today at 01:01 am- MarketScreener

United statesAdam langeDavid kendallAnna krassowskaAdam steensbergHenriette wennickeNovo nordiskZealand pharmaInvestor relations corporate communicationsBoehringer ingelheimDanske bankDrug administrationAmerican diabetes associationEuropean medicines agencyPharma announces financial resultsFirst half

Curis Provides Second Quarter 2023 Business Update

Removal of partial clinical hold – enrolling patients at confirmed RP2D in the TakeAim Leukemia Study Enrolling patients in the TakeAim Lymphoma Study in combination with ibrutinib Strong balance.

United statesJames dentzerExchange commissionRoche groupDrug administrationPrnewswire curis incCuris incTakeaim leukemiaTakeaim lymphoma studyRecent operationalTakeaim leukemia phaseAcute myelogenous leukemiaMyelodysplastic syndromesTakeaim lymphomaJuly registered directAim lymphoma